The detection of pigment-epithelium-derived factor (PEDF) in corneal tissue has allowed greater understanding of the avascularity of corneal tissue. The ability of the cornea to maintain the avascular nature of this tissue, also referred to as the angiogenic privilege of the cornea, could be partly attributed to the presence of this factor. This privilege is severely impaired by various diseases of the ocular surface associated with inflammation and infection that are often followed by neovascularisation, which compromises the transparency of the cornea and results in visual impairment. The rapidly increasing insights into the basic mechanisms controlling neovascularisation, i.e. balance of growth factor activation and enzymatic activity, has most recently led to the development of large-scale use of specific antiangiogenic agents in the treatment of neovascular age-related macular degeneration (AMD). Focusing on the effects of vascular endothelial growth factor (VEGF), the use of such agents, including bevacizumab (Avastin ® ), a humanised anti-VEGF monoclonal antibody originally used in the treatment of metastatic colorectal cancer, has been investigated in corneal angiogenesis. PEDF is only one of the many factors involved in ocular angiogenesis. However, although it is only a small protein, it has strong antiangiogenic actions that are expressed in the retinal pigment epithelial (RPE) layer, as well as in other parts of the eye. There are specific characteristics that could designate a special role for PEDF in the regulation of avascularity in the eye. In this article, we focus on corneal angiogenesis and highlight the special features of this somewhat unexplored cytokine, outlining the current knowledge and possible role of PEDF in corneal neovascularisation.
Pigment-epithelium-derived Factor as a Neuroprotective Factor
Corneal innervation and reinnervation has been shown to be of major importance in corneal wound healing. In this context, the ability of PEDF to protect spinal motor neurons using a culture model based on a specific defect in glutamate transport in amyotrophic lateral sclerosis (ALS) was shown. 20 Additionally, PEDF treatment significantly increases the survival of embryonic chock spinal motor neurons in culture in a dose-dependent way, promoting neurite outgrowth of cultured motor neurons and also preventing death of axotomised motor neurons in vivo.
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The known neurotoxicity of glutamate is considered to be an important mechanism in programmed cell death, and is therefore related to different neurodegenerative disorders. PEDF inhibited glutamate-induced apoptosis in cerebellar granulae cells. 22, 23 This has been shown to be mediated by activation of the transcription factor NF-kappa B (NF-κB); however, PEDF did not regulate the antiapoptotic genes Bcl-2, Bcl-x and Mn-SOD. 24 The earlier detected 44-mer peptide 78-121 out of 418 suggested cell-surface receptors binding to retinoblastoma cells 20 was identified as the PEDF region responsible for its neuroprotective actions. 25 It is not known whether PEDF has similar morphogenic effects within corneal development to those observed in the development of retinal photoreceptors.
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Pigment-epithelium-derived Factor Antiangiogenic Actions in the Eye
As outlined above, there has been significant progress in our understanding of how PEDF may exert its effects. However, the underlying mechanisms concerning the regulation and balance of PEDF and other growth factors involved in angiogenesis of the eye are still unclear.
The first presented antiangiogenic actions of PEDF in the mammalian eye showed that PEDF angiostatin inhibited neovascularisation in the retina more efficiently than the earlier well-studied antiangiogenic factors and, furthermore, that under hypoxia VEGF secretion was high and PEDF expression low.
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Intravitreal injection of PEDF protected retinal photoreceptors from morphological and functional deterioration in light-exposed rats.
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In another model with ischaemic-induced retinopathy in rats, VEGF levels were found to increase to a greater extent than PEDF levels, with a VEGF-PEDF ratio correlating to the observed retinal 
Pigment-epithelium-derived Factor in the Cornea and Tear Fluid
Only a few studies have been conducted so far regarding PEDF in the anterior segment of the eye. PEDF was detected in the tear fluid of some healthy volunteers, suggesting that PEDF may play a role in the regulation of neovascularisation at the ocular surface.
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In normal samples, high levels of PEDF were seen in human corneas with less expression in the conjunctiva, but in patients with pterygia, only very few samples showed faint PEDF staining, and in the remaining samples PEDF was not detectable at all. 59 In the same samples, highly elevated levels of VEGF were seen in the pterygial samples and detectable levels were seen in the conjunctiva, but not in the cornea.
From clinical experience, it is well-known that with the use of amniotic membranes on the ocular surface, less corneal neovascularisation is seen. By investigating human amniotic membranes, PEDF expression was detected, suggesting that PEDF may contribute to the suppression of corneal angiogenesis.
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Matrix Metalloproteinases
The processing and downregulation of PEDF most likely involve major enzymatic factors of wound-healing events, such as matrix 
